Panbela Therapeutics (NASDAQ:PBLA) Announces Quarterly Earnings Results

Panbela Therapeutics (NASDAQ:PBLAGet Rating) posted its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01), MarketWatch Earnings reports. During the same period in the previous year, the business earned ($0.23) EPS.

Shares of NASDAQ:PBLA opened at $1.60 on Friday. The stock’s 50-day moving average is $1.85 and its 200-day moving average is $1.89. Panbela Therapeutics has a 52-week low of $1.45 and a 52-week high of $4.78.

Large investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Panbela Therapeutics in the third quarter valued at about $43,000. Goldman Sachs Group Inc. bought a new stake in shares of Panbela Therapeutics in the third quarter valued at about $52,000. BlackRock Inc. lifted its stake in shares of Panbela Therapeutics by 22.2% in the third quarter. BlackRock Inc. now owns 29,359 shares of the company’s stock valued at $64,000 after buying an additional 5,339 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of Panbela Therapeutics in the third quarter valued at about $72,000. 7.12% of the stock is currently owned by institutional investors.

Several research firms have commented on PBLA. Maxim Group began coverage on shares of Panbela Therapeutics in a research report on Friday. They set a “buy” rating and a $5.00 target price on the stock. Craig Hallum raised their price target on Panbela Therapeutics from $9.00 to $13.00 in a research report on Wednesday, February 23rd. Finally, Zacks Investment Research downgraded Panbela Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th.

About Panbela Therapeutics (Get Rating)

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications.

Featured Articles

Earnings History for Panbela Therapeutics (NASDAQ:PBLA)

Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.